Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04666129 |
Recruitment Status :
Recruiting
First Posted : December 14, 2020
Last Update Posted : June 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Castration-Resistant Prostate Cancer Metastatic Castration-Sensitive Prostate Cancer Non-Metastatic Castration-Resistant Prostate Cancer | Drug: Relugolix Drug: Abiraterone Drug: Prednisone Drug: Methylprednisolone Drug: Apalutamide Drug: Docetaxel | Phase 1 |
This is a three-part, open-label, parallel-cohort study to assess the safety and tolerability of relugolix as the ADT component in combination treatment with abiraterone acetate plus a corticosteroid in patients with mCSPC or mCRPC (Part 1), apalutamide in patients with mCSPC or nmCRPC (Part 2), or docetaxel with or without prednisone in patients with mCSPC or mCRPC (Part 3).
The study will consist of a 45-day screening period followed by a 12-week treatment period with one of the three combination treatments (Parts 1, 2, or 3). All participants are required to have been treated with standard-of-care leuprolide acetate or a GnRH receptor antagonist (such as degarelix) in combination with either abiraterone plus prednisone for a minimum of 12 weeks prior to baseline (Day 1) (Part 1), apalutamide for a minimum of 6 weeks prior to baseline (Day1) (Part 2), or docetaxel for a minimum of one treatment cycle (Part 3). Participants will be transitioned from standard-of-care leuprolide acetate or the GnRH receptor antagonist to relugolix; with relugolix treatment initiated the day the next dose of leuprolide acetate or the GnRH antagonist is scheduled for administration with the prior dosing regimen of abiraterone acetate plus a corticosteroid, apalutamide, or docetaxel with or without prednisone being continued.
In addition to evaluating the safety and tolerability of relugolix, the study will also provide safety data as participants transition from injectable leuprolide acetate or degarelix to treatment with relugolix as the androgen-deprivation component of the treatment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 72 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, Three-Part, Open-Label, Parallel-Cohort Safety and Tolerability Study of Relugolix in Combination With Abiraterone Acetate Plus a Corticosteroid, Apalutamide, or Docetaxel With or Without Prednisone in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer |
Actual Study Start Date : | February 18, 2021 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | November 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Part 1: Relugolix plus Abiraterone plus a Corticosteroid
Participants will receive relugolix in combination with abiraterone plus a corticosteroid for 12 weeks during the study treatment period.
|
Drug: Relugolix
(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day. Other Names:
Drug: Abiraterone Abiraterone acetate (1000 mg [2 x 500-mg tablets]) or fine-particle abiraterone acetate (500 mg [4 x 125-mg tablets]) will be administered orally once daily.
Other Names:
Drug: Prednisone (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily. (Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required. Drug: Methylprednisolone For participants with mCRPC taking fine-particle abiraterone acetate, methylprednisolone 4 mg will be administered orally twice daily.
Other Name: Medrol |
Experimental: Part 2: Relugolix plus Apalutamide
Participants will receive relugolix in combination with apalutamide for 12 weeks during the study treatment period.
|
Drug: Relugolix
(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day. Other Names:
Drug: Apalutamide Apalutamide 240 mg (4 x 60-mg tablets) will be administered orally once daily.
Other Name: Erleada |
Experimental: Part 3: Relugolix plus Docetaxel with or without Prednisone
Participants will receive relugolix in combination with docetaxel with or without prednisone for 12 weeks during the study treatment period.
|
Drug: Relugolix
(Part 1 and Part 3) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 120-mg dose (1 x 120-mg tablets), taken once daily at approximately the same time each day. (Part 2) Relugolix will be administered orally as a single 360-milligram (mg) loading dose of 3 x 120-mg tablets, followed by a 240-mg dose (2 x 120-mg tablets), taken once daily at approximately the same time each day. Other Names:
Drug: Prednisone (Part 1 only) For participants with mCSPC, a 5-mg dose of prednisone will be administered orally once daily, and for participants with mCRPC, a 5-mg dose of prednisone will be administered orally twice daily. (Part 3 only) Prednisone 5 mg can be administered orally twice daily but is not required. Drug: Docetaxel Docetaxel 75 mg/m2 dose will be administered every 3 weeks as a 1-hour intravenous infusion.
Other Names:
|
- Incidence of Adverse Events [ Time Frame: Baseline through Week 13 ]Parts 1, 2, and 3
- Mean Testosterone Serum Concentrations at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]Parts 1 and 2
- Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Week 5, and Week 13 [ Time Frame: Baseline (Day 1), Week 5, and Week 13 ]Parts 1 and 2
- Relugolix Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]Part 2
- Apalutamide and N-desmethyl Apalutamide Trough Concentrations at Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 [ Time Frame: Baseline (Day 1), Week 3, Week 5, Week 9, and Week 13 ]Part 2
- Mean Testosterone Serum Concentrations at Baseline (Day 1), Mid-Treatment, and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment, and Week 13 ]Part 3
- Number and Proportion of Participants with Testosterone Concentrations ≥ 50 ng/dL at Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 [ Time Frame: Baseline (Day 1), Mid-Treatment (Treatment Cycle that Most Closely Corresponds to Week 7 of the Primary Study Treatment Period), and Week 13 ]Part 3
- Relugolix Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]Part 3
- Docetaxel Concentrations at Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel [ Time Frame: Baseline (Day 1), In-Cycle, Mid-Treatment, and Week 13 in Each Infusion Cycle for Docetaxel ]Part 3
- Incidence of Adverse Events [ Time Frame: Up to 52 weeks ]Parts 1, 2, and 3

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
-
A diagnosis of adenocarcinoma of the prostate confirmed by histologic or cytologic evidence and with a documented medical history of either:
-
mCSPC (Parts 1, 2, and 3) defined as having at least two of three risk factors at the baseline (Day 1) visit:
- Total Gleason score of ≥ 6;
- Presence of ≥ 2 metastatic lesions on bone scan;
- Evidence of measurable visceral metastases with exception of hepatic metastases.
- nmCRPC (Part 2 only) defined as disease progression despite maintaining castration levels of testosterone with androgen deprivation therapy (ADT), as evidenced by an increase in consecutive prostate-specific antigen (PSA) concentrations of ≥ 2 ng/mL (2 measurements, at least one week apart).
-
mCRPC (Parts 1 and 3) defined as disease progression despite maintaining castration levels of testosterone with ADT:
- An increase in PSA ≥ 25% and ≥ 2 ng/mL above the nadir, confirmed by 2 measurements at least 3 weeks apart, and;
- The progression of pre-existing disease as evidenced either by worsening symptoms and/or enlarged metastatic lesions; and/or;
- The development of new metastases.
-
-
Currently receiving standard-of-care treatment of leuprolide acetate (3-, 4-, or 6-month injections [intramuscular Lupron or subcutaneous Eligard]) or a gonadotropin-releasing hormone (GnRH) receptor antagonist (such as degarelix) in combination with:
- Part 1: abiraterone acetate 1000 mg or fine-particle abiraterone acetate 500 mg once daily plus prednisone 5 mg once daily for participants with mCSPC or twice daily for participants with mCRPC or methylprednisolone 4 mg once daily and in whom abiraterone has been well tolerated (that is, without evidence of hepatotoxicity requiring dose adjustment for abiraterone) for a minimum of 12 weeks prior to initiation of the study treatment period.
- Part 2: apalutamide 240 mg once daily and in whom apalutamide has been well tolerated (that is, without a fracture, fall, or seizure episode or need to dose adjust due to any adverse events) for a minimum of 6 weeks prior to initiation of the study treatment period.
- Part 3: docetaxel 75 mg/m2 and in whom docetaxel has been well tolerated (that is, no evidence of hypersensitivity reaction, febrile neutropenia or neutrophils < 500 cells/mm3 for more than 1 week, severe or cumulative cutaneous reactions, or moderate neurosensory signs and/or symptoms despite dose reduction) for a minimum of 1 previous treatment cycle.
Key Exclusion Criteria:
- Received treatment with a GnRH analog or GnRH receptor antagonist with either abiraterone acetate plus a corticosteroid (Part 1) or apalutamide (Part 2) in mCSPC participants (Parts 1 and 2) or nmCRPC (Part 2) for a total duration > 24 months or in mCRPC participants (Part 1) for a total duration > 6 months.
-
Abnormal clinical laboratory test value(s) suggestive of clinically unstable underlying disease or a clinical laboratory test value(s) at the screening visit or prior to the baseline (Day 1) visit including:
- (Part 1 only) Serum alanine aminotransferase and/or aspartate aminotransferase > upper limit of normal (ULN) (confirmed twice during screening at least 14 days apart);
- (Part 3 only) Serum alanine aminotransferase and/or aspartate aminotransferase > 1.5 times ULN concurrently with an alkaline phosphatase > 2.5 times ULN;
- (Part 1 only) Total bilirubin > ULN (unless values are consistent with Gilbert's syndrome for which the total bilirubin cannot exceed > 3 times ULN);
- (Part 3 only) Total bilirubin > ULN
- (Part 1 only) Potassium < 3.5 milliequivalents/liter;
- Serum creatinine > 2.0 mg/dL;
- Platelets < 100 × 10^3/microliter (μL);
- Hemoglobin < 10.0 grams/dL;
- Leukocytes < 3 × 10^3/μL;
- Absolute neutrophil count < 1.5 × 10^3/μL;
- Hemoglobin A1c > 8%.
- A medical history within 6 months prior to the screening visit of the following (myocardial infarction; unstable angina; unstable symptomatic ischemic heart disease; New York Heart Association class III or IV heart failure; thromboembolic event[s]), any other significant cardiac conditions, stroke (Part 2 only), transient ischemic attack (Part 2 only), or medical history of seizures (Part 2 only).
- An abnormal electrocardiogram finding
- Uncontrolled hypertension
- Hypotension
- Bradycardia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04666129
Contact: Clinical Trials at Myovant | 650-278-8743 | ClinicalTrials@Myovant.com |
United States, Arizona | |
Urological Associates of Southern Arizona, P.C. | Recruiting |
Tucson, Arizona, United States, 85741 | |
United States, Colorado | |
Colorodo Clinical Research | Recruiting |
Lakewood, Colorado, United States, 80228 | |
United States, Maryland | |
Chesapeake Urology Research Associates | Recruiting |
Baltimore, Maryland, United States, 21204 | |
United States, North Carolina | |
Alliance Urology | Recruiting |
Greensboro, North Carolina, United States, 27403 | |
Wake Forest Baptist Health | Recruiting |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Ohio | |
Clinical Research Solutions | Recruiting |
Middleburg Heights, Ohio, United States, 44130 | |
United States, Pennsylvania | |
Center for Advanced Urology, LLP d/b/a: MidLantic Urology | Recruiting |
Bala-Cynwyd, Pennsylvania, United States, 19004 | |
Keystone Urology Specialists | Recruiting |
Lancaster, Pennsylvania, United States, 17604 | |
United States, South Carolina | |
Carolina Urologic Research Center | Recruiting |
Myrtle Beach, South Carolina, United States, 29572 | |
United States, Tennessee | |
Urology Associates, P.C. | Recruiting |
Nashville, Tennessee, United States, 37209 | |
United States, Texas | |
Urology San Antonio | Recruiting |
San Antonio, Texas, United States, 78229 |
Study Director: | Myovant Medical Monitor | Myovant Sciences |
Responsible Party: | Myovant Sciences GmbH |
ClinicalTrials.gov Identifier: | NCT04666129 |
Other Study ID Numbers: |
MVT-601-049 |
First Posted: | December 14, 2020 Key Record Dates |
Last Update Posted: | June 2, 2022 |
Last Verified: | May 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
mCRPC mCSPC Relugolix Abiraterone Prednisone Leuprolide acetate |
nmCRPC Apalutamide Docetaxel Degarelix Methylprednisolone |
Prostatic Neoplasms Hypersensitivity Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Prostatic Diseases Immune System Diseases Prednisone Methylprednisolone Docetaxel Relugolix Antineoplastic Agents Tubulin Modulators Antimitotic Agents |
Mitosis Modulators Molecular Mechanisms of Pharmacological Action Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antiemetics Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents Androgen Antagonists |